Hepion interim CEO granted 1.35M stock options

Hepion Pharmaceuticals, Inc. (HEPA) reported that Interim CEO and director Gary S. Stetz received a grant of stock options for 1,345,500 shares of common stock.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that Interim CEO and director Gary S. Stetz received a grant of stock options for 1,345,500 shares of common stock. The options have an exercise price of $0.08 per share and expire on August 19, 2036. According to the grant terms, 336,375 options vest immediately, and the remaining options vest in equal monthly installments over six months from the grant date.

Insider Trade Summary

Grant/Award: 1,345,500 shares

Grant/Award 1 txn

Insider Stetz Gary S.

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	1,345,500	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,345,500 contracts (Direct)

Footnotes (1)

1. F1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

Key Figures

Stock options granted: 1,345,500 options Exercise price: $0.08 per share Options vesting upon grant: 336,375 options +3 more

6 metrics

Stock options granted 1,345,500 options Grant of stock options to Interim CEO Gary S. Stetz on 2026-08-19

Exercise price $0.08 per share Conversion or exercise price of granted stock options

Options vesting upon grant 336,375 options Portion of options that vest immediately on grant date

Remaining options vesting period 6 months Remaining options vest in equal monthly amounts over six months from grant

Expiration date August 19, 2036 Expiration of granted stock options

Options held after transaction 1,345,500 options Total derivative securities following the grant

Key Terms

Stock Options, exercise price, vesting, expiration date

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price: "0.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"336,375 options vest upon grant and the remaining amount vests"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-08-19""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HEPA report for Gary S. Stetz?

Hepion Pharmaceuticals (HEPA) reported that Interim CEO Gary S. Stetz received a grant of 1,345,500 stock options to purchase common stock at an exercise price of $0.08 per share, expiring on August 19, 2036.

What is the vesting schedule of the new HEPA stock options granted to Gary S. Stetz?

Of the 1,345,500 Hepion (HEPA) stock options granted to Gary S. Stetz, 336,375 vest upon grant, and the remaining options vest in equal amounts monthly over six months from the date of grant.

What is the exercise price of Gary S. Stetz’s new HEPA stock options?

The exercise price of Gary S. Stetz’s new Hepion (HEPA) stock options is $0.08 per share for 1,345,500 underlying shares of common stock.

When do the newly granted HEPA stock options to Gary S. Stetz expire?

The stock options granted to Gary S. Stetz by Hepion (HEPA) expire on August 19, 2036, giving him the right to purchase shares at $0.08 per share until that date, subject to vesting.

How many HEPA derivative securities does Gary S. Stetz hold after this option grant?

Following this transaction, Gary S. Stetz holds 1,345,500 stock options related to Hepion (HEPA) common stock as reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:37 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stetz Gary S.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		1,345,500		08/19/2026(1)	08/19/2036	Common Stock	1,345,500	$0	1,345,500	D

Explanation of Responses:

1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

	/s/ Gary S. Stetz	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)